Short answer
Akebia Therapeutics, Inc. (AKBA) filed its Q2 2026 10-Q quarterly report on Aug 5, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $49M (down 21.4% year over year) with net income of −$9M.
Q2 2026 key financials · XBRL
- Revenue
- $49M
- −21.4% YoY · −8.2% QoQ
- Net income
- −$9M
- −3706.5% YoY · +1.6% QoQ
- Operating margin
- -12.9%
- EPS (diluted)
- −$0.04
- −300.0% YoY · −33.3% QoQ
Source: XBRL data from the Akebia Therapeutics, Inc. (AKBA) Q2 2026 10-Q on SEC EDGAR. USD.
Akebia Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Commercial portfolio: Vafseo launched January 2025; Auryxia reached loss of exclusivity March 2025
- Worst product outlook: Auryxia generic entered market after Teva ANDA approval on March 11, 2026
- R&D expenses $1.8B cumulatively through June 30, 2026
- Near-term headwinds: Auryxia generic competition and significant ongoing R&D expenditures
Risk Factors
- Continued losses and uncertain profitability from high R&D and commercialization costs
- Refinancing dependency for senior secured term loan, with principal payments otherwise starting January 1, 2027
- Funding runway of at least two years contingent on product, royalty, supply and license revenues
- Product approval and commercial viability risk despite two approved products, Auryxia and Vafseo
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Akebia Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.